Filing Details

The remainder of this cover page shall be filled out for a reporting persons initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter disclosures provided in a prior cover page.

  Name of Reporting Person:

  Novo Holdings A/S

  Check the Appropriate Box if a Member of Group (See Instructions):

  (a)  ☐        (b)  ☐

  SEC Use Only:

  Source of Funds:

  WC

  Check if Disclosure of Legal Proceedings is Required Pursuant to Items 2(d) or 2(e):

  ☐

  Citizenship or Place of Organization:

  Denmark

Number of

Shares

 Beneficially 

Owned By

Each

Reporting

Person

With:

  Sole Voting Power:

  2,400,000

  Shared Voting Power:

  0

  Sole Dispositive Power:

  2,400,000

  Shared Dispositive Power:

  0

  Aggregate Amount Beneficially Owned by Each Reporting Person:

  2,400,000

  Check if the Aggregate Amount in Row (11) Excludes Certain Shares:

  ☐

13.

  Percent of Class Represented By Amount In Row (11):

  9.13% (1)

  Type of Reporting Person:

  CO

Based upon 26,289,087 shares of the Issuers Common Shares outstanding as of December 31, 2022, as reported in the Issuers Form 20-F filed with the Securities and Exchange Commission (the SEC) on April 11, 2023.

Novo Holdings A/S, a Danish corporation, is an investment firm focused on life sciences and finance that is wholly owned by Novo Nordisk Foundation (the Foundation), a Danish commercial foundation. Novo Holdings A/S is the holding company in the group of Novo companies (currently comprised of Novo Nordisk A/S and Novozymes A/S) and is responsible for managing the Foundations assets, including its financial assets. Based on the governance structure of Novo Holdings A/S and the Foundation, the Foundation is not deemed to have any beneficial ownership of the securities of the Issuer held by Novo Holdings A/S.

The business address of both Novo Holdings A/S and the Foundation is Tuborg Havnevej 19, 2900 Hellerup, Denmark.

Novo Holdings A/S, a holding company that is responsible for managing the Foundations assets, provides seed and venture capital to development stage companies and invests in well-established companies within the life science and biotechnology sector.

Within the last five years, neither Novo Holdings A/S, the Foundation, nor any person named in the updated Schedule I has been convicted in any criminal proceedings.

Within the last five years, neither Novo Holdings A/S, the Foundation, nor any person named in the updated Schedule I was a party to a civil proceeding of a judicial or administrative body of competent jurisdiction and as a result of such proceeding was or is subject to a judgment, decree or final order enjoining future violations of, or prohibiting or mandating activities subject to, federal or state securities laws or finding any violation with respect to such laws.

On June 5, 2023, Novo Holdings A/S sold 470,558 shares a weighted average price of $2.1726 per share in the open market.

On June 5, 2023, Novo Holdings A/S sold 200,000 shares at $1.60 per share in a block trade.

Novo Holdings A/S beneficially owns 2,400,000 shares of Common Shares (the Novo Shares) representing approximately 9.13% of the Issuers outstanding shares of Common Shares, based upon 26,289,087 shares of the Issuers Common Shares outstanding as of December 31, 2022, as reported in the Issuers Form 20-F filed with the SEC on April 11, 2023.

Novo Holdings A/S is a Danish corporation wholly owned by the Novo Nordisk Foundation. Novo Holdings A/S has the sole power to vote and dispose of the Novo Shares. Neither the Foundation nor any person listed on the updated Schedule I has the power to direct the vote as to, or the disposition of the Novo Shares.

Except as described in Item 3, Novo Holdings A/S has not effected any transactions in the Issuers Common Shares within the past 60 days and neither the Foundation nor any person listed on the updated Schedule I has effected any transactions in the Issuers Common Shares within the past 60 days.

Novo Holdings A/S does not know of any other person having the right to receive or the power to direct the receipt of dividends from, or the proceeds from the sale of, the Novo Shares.

Not Appliable

/s/ Barbara Fiorini Due

Novo Holdings A/S

Name, Title

Address

Principal Occupation

Citizenship

Lars Rebien Sørensen,

Chairman of the Board

Christianholms Tværvej 27, 2930 Klampenborg

Denmark

Steen Riisgaard,

Vice Chairman of the Board

Hestetangsvej 155,

3520 Farum,

Denmark

United Kingdom

United States

Kløvervang 10,

2970 Hørsholm,

Denmark

Novo Nordisk Foundation

Name, Title

Address

Principal Occupation

Citizenship

Lars Rebien Sørensen,

Chairman of the Board

Christianholms Tværvej 27

2930 Klampenborg

Denmark

Lars Henrik Munch,

Vice Chairman of the Board

Galionsvej 46

1437 Copenhagen K

Denmark

Mads Krogsgaard Thomsen,

Chief Executive Officer

Præstevejen 38

3230 Græsted

Denmark

Ole Jakob Müller,

Director

Lars Henrik Fugger,

Director

72 Staunton Road, Headington

OX3 7TP Oxford
Great Britain

Liselotte Højgaard,

Director

Grønningen 21, 4.

1270 Copenhagen K

Denmark

Mads Boritz Grøn,

Director

Horsevænget 4

3400 Hillerød

Denmark

Steen Riisgaard,

Director

Stig Strøbaek,

Director

Nana Sejbæk

Director

Vinrankevej 3

2900 Hellerup

Denmark

Christopher Ashby Voigt

Director

57 Elizabeth Rd

Belmont, MA 02478

USA